CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 130 target
Drug / intervention
Etomidate +4 moredrug
Likely dose
Etomidate 0.15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00415701
NCT00415701Phase 4Completed
CompareCT.gov

Effect of an Anesthetic Induction Dose of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery

Insel Gruppe AG, University Hospital Bern·interventional·Posted Dec 25, 2006·Updated Mar 4, 2010

In Brief

A Phase 4 clinical trial evaluating Etomidate, Propofol, and 3 other interventions for Coronary Artery Disease and Mitral Valve Regurgitation. Completed, enrolled 130 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effect of a single dose of etomidate for patients undergoing cardiac surgery with the use of cardiopulmonary bypass (CPB) on post-CPB adrenocortical responsiveness, on requirements of hemodynamic support, and on use of intensive care resources.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease, Mitral Valve Regurgitation
CountriesSwitzerland
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 25, 2006
Enrollment StartNov 1, 2006
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 19.5 years ago

Interventions

Etomidatedrug

Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg

Propofoldrug

Single induction dose of propofol 2%; total dose 1.5 mg/kg

Hydrocortisonedrug

Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x

NaCl 0.9%drug

NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x

Tetracosactinother

Diagnostic test, Tetracosactin 250 microg iv